조영제 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The contrast media market reached USD 6.20 billion in 2025 and is forecast to climb to USD 8.88 billion by 2030, reflecting a 7.44% CAGR over the forecast period.

Expansion stems from the steady rise in diagnostic imaging volumes, faster regulatory approvals for macrocyclic gadolinium agents, and continuing investment in manufacturing capacity that safeguards supply. Hospitals are streamlining protocols to favor safer macrocyclic formulations while also broadening the use of low-dose iodinated agents to curb adverse events. Vendors are racing to automate dosing through AI-enabled injectors, which shrink waste and help imaging centers clear patient backlogs. Sustainability now sits alongside safety as a core purchasing criterion, prompting research into biodegradable or manganese-based alternatives. At the same time, the shift of routine imaging to ambulatory sites is redistributing demand toward smaller-batch packaging and single-patient delivery systems.

Global Contrast Media Market Trends and Insights

Macrocyclic Gadobutrol and Gadopiclenol: Fast-Tracked Approvals Boosting Demand

Worldwide regulators are fast-tracking macrocyclic compounds such as gadobutrol and gadopiclenol because they retain less gadolinium in body tissues than their linear predecessors. The European Medicines Agency has already removed several linear formulations from the market, spurring hospitals to convert MRI protocols. German Cancer Research Center data confirm macrocyclic agents' lower tissue retention, an assurance that resonates with neurologists and cardiologists who perform repeated follow-up scans. As roughly 400 million gadolinium doses are administered each year, the protocol switch creates a sizeable replacement cycle that lifts both unit demand and average selling prices. Vendors that secured early-stage approvals now leverage extended exclusivity to fund next-generation chelates with even tighter molecular cages. North American payers are also updating reimbursement schedules to favor macrocyclic agents, accelerating adoption curves, and helping the contrast media market add volume without sacrificing margin.

AI-driven Automated Injection Systems Reducing Waste

Smart injectors combine patient weight, glomerular filtration rate, and scan type to modulate flow rates in real time. European Congress of Radiology research presented in 2024 showed average contrast savings of 30% per CT scan without sacrificing diagnostic clarity. When integrated with picture archiving and communication systems (PACS), the software automatically logs batch numbers to help track pharmacovigilance data. Imaging suites report time savings of up to three minutes per exam, translating to extra scan slots and higher room utilization. In markets recovering from pandemic-related shortages, the waste-reduction feature doubles as a business continuity lever. Manufacturers are embedding proprietary algorithms into closed-loop hardware, creating high switching costs that strengthen competitive positioning in the contrast media market.

Global Iodine Price Volatility Pressuring OEM Margins

Iodine spot prices tripled between 2021 and 2023, hammering cost structures for iohexol and iodixanol producers. The 2022 Shanghai lockdown underscored the fragility by cutting GE Healthcare's output 80%, forcing hospitals to slash usage by up to 85%. Manufacturers are now dual-sourcing raw iodine from Chile and Japan, but freight costs and geopolitical risks persist. Some vendors trial lower-iodine formulations, yet those can raise dose volumes, neutralizing savings. Insurers rarely adjust reimbursement fast enough to cover sudden input spikes, squeezing gross margins and slowing capital expenditure on new plants. Until price volatility abates, procurement officers will favor vendors with diversified supply, subtly reshaping buyer preferences within the contrast media market.

Other drivers and restraints analyzed in the detailed report include:

1. Rise of Point-of-Care Ultrasound Boosting Microbubble Uptake
2. Growing Environmental Scrutiny Over Gadolinium Wastewater

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Iodinated solutions represented 62.1% of the contrast media market in 2024, buoyed by CT's central role in emergency and oncologic diagnostics. That leadership persists even as supply shocks highlight the need for dual sourcing and low-concentration formulations. Vendors are optimizing viscosity and osmolality to pair with photon-counting CT scanners that deliver high-resolution images using 40% less iodine. The iodinated category also benefits from entrenched reimbursement pathways across most OECD nations. Yet growth rates are moderating as environmental and renal safety considerations drive experimentation with alternative chemistries.

The microbubble segment, fueled by point-of-care ultrasound, is on track for a 14.8% CAGR through 2030. Adoption jumps when emergency physicians see that microbubbles amplify myocardial perfusion imaging in under five minutes without ionizing radiation exposure. Start-ups are working on lyophilized formulations that extend shelf life to two years, positioning microbubbles for adoption in low-resource settings. Regulatory green lights in Japan for pediatric liver indications further widen the addressable pool. As a result, microbubbles offer the strongest incremental lift to the contrast media market size at the segment level.

X-ray/CT preserved 69.2% of the overall contrast media market size in 2024 because CT remains the first-line modality for trauma, stroke, and cancer staging. Photon-counting detectors promise sharper images at lower doses, potentially sustaining volume growth even in mature regions. However, modality-specific dose-optimization software is lowering per-scan milliliter usage, tempering revenue growth linked to volume alone. Meanwhile, vendors tie contrast sales to long-term equipment service contracts, locking in hospital loyalty.

Ultrasound's projected 11.5% CAGR to 2030 hinges on microbubble breakthroughs that push the modality beyond anatomical imaging into real-time tissue perfusion assessment. Molecularly targeted microbubbles targeting VEGF-expressing tumors are in early trials, suggesting future substitutions away from MRI in certain oncology workflows. Broader ultrasound use in obstetrics and emergency rooms widens the user base, spreading awareness of contrast-enhanced capabilities. Collectively, these developments fortify ultrasound's role in expanding the contrast media market.

The Contrast Media Market is Segmented by Type (Iodinated Contrast Media, Gadolinium-Based Contrast Media, Microbubble Contrast Media, and More), Imaging Modality (X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and More), Indication (Cardiovascular Diseases, Oncology, and More), End-User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More).

Geography Analysis

North America held 36.18% of the contrast media market in 2024 on the back of extensive imaging infrastructure and reimbursement systems that reward advanced modalities. Macrocyclic GBCA usage exceeds 90% of all MRI contrast doses, illustrating rapid compliance with safety advisories. Neuroscans tied to Alzheimer's and multiple-sclerosis monitoring contribute steady baseline demand, while cardiac CT programs expand in response to updated chronic coronary disease guidelines. AI-driven injectors roll out quickly due to strong venture-capital backing for health-tech, giving U.S. facilities early access to waste-cutting innovations that shield them from raw-material price shocks.

Asia-Pacific is the fastest-growing region through 2030, lifted by China's large procedural volume, India's widening radiology footprint, and Japan's ongoing technology upgrades. China's national procurement policy for low-iodine agents catalyzes volume growth without proportional iodine consumption, reinforcing resilient supply chains. In October 2024, FUJIFILM secured domestic approval for a pediatric microbubble agent, signaling regulatory openness to novel formulations and expanding the addressable patient pool. Public-private partnerships in India fund new CT installations in tier-2 cities, bringing contrast-enhanced imaging to previously underserved populations and bolstering overall contrast media market growth.

Europe maintains a stable base demand while leaning into sustainability. Several national health services offer financial bonuses for hospitals deploying macrocyclic GBCAs or implementing wastewater capture. April 2025 preclinical results from Sweden's Spago Nanomedical on a nanoparticle MRI agent illustrate the region's contribution to green chemistry innovation. Larger EU hospitals join consortiums to evaluate manganese contrast agents, anticipating future gadolinium disposal rules. As regulations tighten, European purchasing policies will likely favor vendors with clear environmental roadmaps, influencing competitive dynamics in the contrast media market.

1. Bayer
2. GE Healthcare
3. Bracco Imaging S.p.A
4. Guerbet Group
5. Lantheus
6. FUJIFILM
7. Beijing Beilu Pharmaceutical Co. Ltd.
8. Taejoon Pharm Co. Ltd.
9. Spago Nanomedical
10. Nano Therapeutics (NTI Ltd.)
11. Jiangsu Hengrui Medicine Co. Ltd.
12. Fresenius
13. NanoPET Pharm GmbH
14. Starry Pharma Group Co. Ltd.
15. Guerbet U.S. Holdings Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerated Approvals of Macrocyclic Gadobutrol and Gadopiclenol across Globe Raising Replacement Demand
  • 4.2.2 Rapid Deployment of Low-Dose Iodinated Agents in China to Address Iodine Supply Constraints
  • 4.2.3 AI-Driven Automated Injection Systems Reducing Contrast Waste and Enabling Higher Scan Throughput
  • 4.2.4 Rise of Point-of-Care Ultrasound in Emergency Departments Fueling Microbubble Agent Uptake
  • 4.2.5 Insurance Reimbursement Expansion for Contrast-Enhanced Mammography in EU-5 Boosting Procedural Volumes
  • 4.2.6 Transition to Out-patient Cardiac CT in the U.S. Following CMS OPPS Updates
• 4.3 Market Restraints
  • 4.3.1 Global Iodine Supply Price Volatility Pressuring OEM Margins
  • 4.3.2 Growing Environmental Scrutiny Over Gadolinium Waste-water Emissions
  • 4.3.3 Adverse Reaction Litigation Dampening Physician Adoption of Novel Agents
  • 4.3.4 Imminent EU MDR Restrictions on Linear Gadolinium Agents Tightening Product Portfolios
• 4.4 Value Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Type
  • 5.1.1 Iodinated Contrast Media
  • 5.1.2 Gadolinium-based Contrast Media
  • 5.1.3 Microbubble Contrast Media
  • 5.1.4 Barium-based Contrast Media
  • 5.1.5 Others
• 5.2 By Imaging Modality
  • 5.2.1 X-ray / Computed Tomography (CT)
  • 5.2.2 Magnetic Resonance Imaging (MRI)
  • 5.2.3 Ultrasound
  • 5.2.4 Nuclear Imaging (SPECT / PET)
• 5.3 By Indication
  • 5.3.1 Cardiovascular Diseases
  • 5.3.2 Oncology
  • 5.3.3 Gastrointestinal Disorders
  • 5.3.4 Neurological Disorders
  • 5.3.5 Nephrological Disorders
  • 5.3.6 Musculoskeletal Disorders
  • 5.3.7 Other Indications
• 5.4 By End-user
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Ambulatory Surgery Centers
  • 5.4.4 Academic & Research Institutes
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Bayer AG
  • 6.3.2 GE HealthCare
  • 6.3.3 Bracco Imaging S.p.A
  • 6.3.4 Guerbet Group
  • 6.3.5 Lantheus Medical Imaging Inc.
  • 6.3.6 FUJIFILM Corporation
  • 6.3.7 Beijing Beilu Pharmaceutical Co. Ltd.
  • 6.3.8 Taejoon Pharm Co. Ltd.
  • 6.3.9 Spago Nanomedical AB
  • 6.3.10 Nano Therapeutics (NTI Ltd.)
  • 6.3.11 Jiangsu Hengrui Medicine Co. Ltd.
  • 6.3.12 Fresenius Kabi AG
  • 6.3.13 NanoPET Pharm GmbH
  • 6.3.14 Starry Pharma Group Co. Ltd.
  • 6.3.15 Guerbet U.S. Holdings Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment